Possible association of medications during pregnancy with low estriol level of the triple antenatal screening test

References

• Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, Désilets VA, et al.; Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008;30:918–949.
   PubMedGoogle Scholar
• Mastorakos G, Ilias I. Maternal and fetal hypothalamic-pituitary-adrenal axes during pregnancy and postpartum. Ann N Y Acad Sci 2003;997:136–149.
   PubMed Web of Science ®Google Scholar
• Zalel Y, Kedar I, Tepper R, Chen R, Drugan A, Fejgin M, Beyth Y. Differential diagnosis and management of very low second trimester maternal serum unconjugated estriol levels, with special emphasis on the diagnosis of X-linked ichthyosis. Obstet Gynecol Surv 1996;51:200–203.
   PubMedGoogle Scholar
• Craig WY, Haddow JE, Palomaki GE, Kelley RI, Kratz LE, Shackleton CH, Marcos J, et al. Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome. Prenat Diagn 2006;26:842–849.
   PubMedGoogle Scholar
• Lambert-Messerlian GM, Eklund EE, Malone FD, Palomaki GE, Canick JA, D’Alton ME. Stability of first- and second-trimester serum markers after storage and shipment. Prenat Diagn 2006;26:17–21.
   PubMed Web of Science ®Google Scholar
• Pekarek DM, Chapman VR, Neely CL, Ramsey PS, Biggio JR. Medication effects on midtrimester maternal serum screening. Am J Obstet Gynecol 2009;201:622.e1–622.e5.
   Google Scholar
• Hörmansdörfer C, Corral A, Scharf A, Vaske B, Hillemanns P, Schmidt P. [Comparison of current methods of prenatal screening for down syndrome]. Rev Esp Salud Publica 2010;84:43–51.
   PubMedGoogle Scholar
• The Food and Drug Administration and American Thyroid Association. Propylthiouracil-Related Liver Toxicity: Public Workshop, April 19, 2009, Washington, D.C.
   Google Scholar
• . AHFS drug information 2007McEvoy GK, ed. Propylthiouracil. Bethesda, MD: American Society of Health-System Pharmacists; 2007:3253–3254.
   Google Scholar
• Drews K, Seremak-Mrozikiewicz A. The optimal treatment of thyroid gland function disturbances during pregnancy. Curr Pharm Biotechnol 2011;12:774–780.
   PubMed Web of Science ®Google Scholar
• Anderson GD. Developmental pharmacokinetics. Semin Pediatr Neurol 2010;17:208–213.
   PubMed Web of Science ®Google Scholar
• Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab 2009;10:520–529.
   PubMed Web of Science ®Google Scholar
• Lang T, Haberl M, Jung D, Drescher A, Schlagenhaufer R, Keil A, Mornhinweg E, et al. Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11). Drug Metab Dispos 2006;34:1582–1599.
   PubMed Web of Science ®Google Scholar
• Pollex EK, Hutson JR. Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents. Expert Opin Drug Metab Toxicol 2011;7:325–339.
   PubMed Web of Science ®Google Scholar
• Wickham EP 3rd, Ewens KG, Legro RS, Dunaif A, Nestler JE, Strauss JF 3rd. Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011;96:E719–E727.
   PubMed Web of Science ®Google Scholar
• Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155–1162.
   PubMed Web of Science ®Google Scholar
• Tomalik-Scharte D, Maiter D, Kirchheiner J, Ivison HE, Fuhr U, Arlt W. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur J Endocrinol 2010;163:919–924.
   PubMed Web of Science ®Google Scholar
• Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder SM, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004;363:2128–2135.
   PubMed Web of Science ®Google Scholar
• Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004;36:228–230.
   PubMed Web of Science ®Google Scholar
• Huq MD, Tsai NP, Gupta P, Wei LN. Regulation of retinal dehydrogenases and retinoic acid synthesis by cholesterol metabolites. EMBO J 2006;25:3203–3213.
   PubMedGoogle Scholar
• McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 2003;53:1–114.
   PubMed Web of Science ®Google Scholar
• Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab 2009;10:520–529.
   PubMed Web of Science ®Google Scholar
• Barre J, Houin G, Brunner F, Bree F, Tillement JP. Disease-induced modifications of drug pharmacokinetics. Int J Clin Pharmacol Res 1983;3:215–226.
   PubMedGoogle Scholar
• Yanai N, Shveiky D. Fetal hydrops, associated with maternal propylthiouracil exposure, reversed by intrauterine therapy. Ultrasound Obstet Gynecol 2004;23:198–201.
   PubMed Web of Science ®Google Scholar
• Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010;31:702–755.
   PubMed Web of Science ®Google Scholar